Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report.

ABSTRACT:

Background

Fulminant myocarditis has been reported in patients treated with immune checkpoint inhibitors. We present the first described case of acute immune-mediated myocarditis and myositis associated with durvalumab plus tremelimumab combination therapy. The patient was undergoing treatment for advanced endometrial cancer.

Case presentation

A 75-year-old Caucasian female presented with difficulty ambulating due to neck protraction, imbalance, and increased shortness of breath with exertion 3 weeks after her first durvalumab and tremelimumab administration for advanced endometrial cancer. While the patient's initial laboratory data showed an acute transaminitis and elevated creatine phosphokinase (CPK), consistent with myositis, she developed complete heart block and ventr

SUBMITTER: Mahmood SS 

PROVIDER: S-EPMC6005798 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature